SureSeq™ CLL + CNV Panel

Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia in adults. A wide variety of chromosomal abnormalities are associated with CLL, ranging from single nucleotide variants (SNVs) and insertions/deletions (indels) up to large copy-number variations (CNVs), including trisomies.

The SureSeq CLL + CNV Panel has been designed in collaboration with recognised cancer experts to detect 12 key genes and 5 chromosomal regions implicated in CLL progression (Table 1). The SureSeq CLL + CNV Panel alleviates the burden of running multiple assays and streamlines your CLL research to deliver a comprehensive genomic profile for each CLL sample using a single workflow.

The SureSeq CLL + CNV Panel offers:

• Unparalleled uniformity and high depth of coverage - detect low-frequency SNVs and indels
  with confidence
• CNV detection ranging from loss of single exons to full chromosome arms and
  trisomy 12 - profile your samples for CNVs in the 5 most commonly aberrant regions in CLL
• Time savings - replace multiple assays with a single NGS panel, increasing throughput and
  reducing turnaround time
• Complimentary data analysis software - analyse your data with Interpret, OGT’s powerful and
  easy-to-use analysis solution for accurate identification of all variants and CNVs

Contains the latest evidence-based content

Investigating both chromosomal aberrations and SNVs/indels is imperative to advance research into CLL progression and treatment. Structural abnormalities are common in CLL and found in more than 80% of CLL cases, the most frequent being del(13q), del(11q), del(17p), del(6q) and trisomy 12¹. Some of these CNVs cover important tumour suppressors, such as del(17p) resulting in the loss of the TP53 gene. More recently, other genes have also been found to be mutated in CLL, including NOTCH1, SF3B1, MYD88 and BIRC3, adding to the genomic complexity of this leukaemia².

Due to this genetic heterogeneity, current analysis strategies for CLL require multiple methods to obtain a comprehensive genetic picture, often using microarray or fluorescence in situ hybridisation (FISH) to detect structural abnormalities in combination with NGS for somatic variants. With OGT’s SureSeq CLL + CNV Panel, you can now obtain a more complete understanding of the genetic makeup of CLL progression in each sample using a single assay.

Table 1: The SureSeq CLL + CNV Panel targets the 5 most common chromosomal regions implicated in CLL and 14 genes, including 2 genes and 24 SNPs for easy sample tracking.

Superior coverage uniformity allowing reliable variant and somatic CNV detection

OGT’s expert bait design delivers outstanding uniformity and depth of coverage, offering confident detection of low frequency SNVs and indels down to 1% minor allele frequency (MAF) in 14 genes (Figure 1), including 2 genes and 24 SNPs to allow for easy sample tracking³.

Figure 1: Illustration of the excellent uniformity and high depth of coverage allowing confident detection of (A) a SF3B1 exon 15 hotspot variant Lys700Glu with 4.8% allele frequency and (B) a TP53 exon 4 frameshift deletion (TP53 c.124del) with frequency 38.9%.

The SureSeq CLL + CNV Panel covers the 5 most common CNVs in CLL and enables detection down to 10% MAF, corresponding to 20% tumour content. Compared to array data, often considered the gold standard for CNV detection, the events reported with the SureSeq CLL + CNV Panel were 100% concordant, even in genomic regions containing multiple aberrations (Figures 2 - 3). More so, facilitated by OGT’s excellent bait design, loss-of-heterozygosity (LOH) can be identified. With a CNV size detection range from single exon to whole gene, up to complete loss of a chromosomal arm and whole chromosome gains (trisomy 12), your data provides a more comprehensive genetic picture for each sample from a single assay.

Figure 2: 42.7Mb deletion of 11q covering ATM.

Figure 3: 0.6Mb biallelic loss called within a larger ~1Mb single allele deletion in the region covering DLEU2/DLEU1/DLEU7 on chromosome 13q.

Complimentary Interpret software

Interpret is OGT’s powerful and easy-to-use data analysis solution, facilitating analysis and visualisation of a wide range of somatic variants and structural aberrations. Designed to work seamlessly with all SureSeq panels, Interpret perfectly complements the SureSeq CLL + CNV Panel, delivering fast and accurate detection of all SNVs, indels, LOH and CNVs covered by the panel. Following detection, all events can be readily visualised in the user-friendly variant browser, for an effortless translation of all your CLL data into meaningful results (Figure 4).

Figure 4: Following analysis, all variants and CNVs are visualised for easy interpretation in OGT’s Interpret. In this example a trisomy 12 is detected, showing a reliable gain call across the whole chromosome.

Bespoke panel content

Does the SureSeq CLL + CNV Panel not meet your exact requirements? With OGT, you never have to sequence genes you’re not interested in and can always modify each panel to what’s most relevant for your research. Choose from our regularly updated, expert-curated library of pre-optimised cancer content to create your ideal custom SureSeq myPanel™ CLL Panel, or order the SureSeq CLL + CNV Panel right off the shelf.

Create custom CLL Panel >

Order the SureSeq CLL + CNV Panel >

The SureSeq CLL + CNV Panel in numbers

Ordering information

* Only for use with OGT's NGS panels

References

1. Döhner et al., N Engl J Med 2000;343:1910-1916
2. Rossi et al., Blood 2013;121:1403-1412
3. Pengelly et al., Genome Med 2013;5:89

Disclaimer

SureSeq: For Research Use Only; Not for Diagnostic Procedures. This webpage and its contents are © Oxford Gene Technology IP Limited – 2020. All rights reserved. OGT™ and SureSeq™ are trademarks of Oxford Gene Technology IP Limited. The SureSeq NGS Library Preparation Kit was jointly developed between Oxford Gene Technology and Bioline Reagents Limited. Dynabeads is a trademark of Thermo Fisher Scientific and AMPure® is a registered trademark of Beckman Coulter Inc.